. Calvez, Virological and pharmacological factors associated with virological 308, 2005.

D. 'aquila, L. M. Demeter, S. M. Hammer, V. A. Johnson, C. Loveday et al., Antiretroviral drug resistance testing in 321 adults infected with human immunodeficiency virus type 1, p.322, 2003.

J. H. Huitema and . Beijnen, Practical guidelines to interpret plasma 331 concentrations of antiretroviral drugs, Clin Pharmacokinet, vol.43, issue.332, pp.845-53, 2004.

D. J. Livington, S. Pazhanisamy, D. J. Porter, J. A. Partaledis, R. D. Tung et al., Weak Binding of VX-478 to Human Plasma Proteins and Implications for Anti-Human Immunodeficiency Virus Therapy, Guillevic, D. Descamps, pp.1238-1283, 1995.
DOI : 10.1093/infdis/172.5.1238

A. G. Marcelin, C. Dalban, G. Peytavin, C. Lamotte, and R. Agher, Virological and Pharmacological Parameters Predicting the Response to Lopinavir-Ritonavir in Heavily Protease Inhibitor-Experienced Patients, Antimicrobial Agents and Chemotherapy, vol.49, issue.5, pp.1720-1726
DOI : 10.1128/AAC.49.5.1720-1726.2005